After the screening, we selected a CHRM4 candidate inhibitor, ceritinib, to test its pharmacological effects on prostate cancer cells compared to known CHRM4 inhibitors (LY2033298 and PD102807) (Table 1). The gene discussed is CHRM4; the disease is prostate cancer.